Drugs / NNC9204-1706 A
last change Aug 2017 re-read 3 minutes ago

NNC9204-1706 A

Investigated by
Novo Nordisk A/S

Trials 1

20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03095807 Mar → Aug 2017 metabolic disease, obesity disorder Novo Nordisk A/S Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as NNC9204-1706 A ClinicalTrials.gov intervention name — accepted as the source's own label NCT03095807 ↗
Route Subcutaneous “Administered subcutaneously (s.c., under the skin)” NCT03095807 ↗